![]() ![]() “Currently approved oral antidepressants work primarily via monoamine pathways,” investigators explained. Led by chief executive officer Herriot Tabuteau, MD, the Axsome research team sought to compare mean MADS score change in patients randomized to either dextromethorphan-bupropion or bupropion from baseline to each week of treatment through 6 weeks. ![]() #Wellbutrin insomnia trialThey also offer differentiated outcomes for clinical assessment of depression-a field which due to increasing rates of placebo-controlled assessments has reported an approximate 50% clinical trial signal response rate in the last 25 years, according to the investigators. The new findings from the ASCEND trial contribute to the clinical profile of the Axsome Therapeutics agent, which previously received breakthrough therapy designation by the US Food and Drug Administration (FDA). In a randomized, double-blind, multi center, parallel-group study of the NMDA/sigma-1 receptor antagonist combination therapy, investigators observed significant improvements in the Montgomery-Asberg Depression Rating Scale (MADRS) of adults with major depression treated with dextromethorphan-bupropion versus those treated with lone antidepressant bupropion. Investigative therapy dextromethorphan-bupropion (AXS-05) provided significantly improved major depression symptoms versus lone sustained-release bupropion while remaining tolerable in adult patients over 6 weeks, according to new phase 2 trial findings. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |